[go: up one dir, main page]

MX2020013567A - Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes. - Google Patents

Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes.

Info

Publication number
MX2020013567A
MX2020013567A MX2020013567A MX2020013567A MX2020013567A MX 2020013567 A MX2020013567 A MX 2020013567A MX 2020013567 A MX2020013567 A MX 2020013567A MX 2020013567 A MX2020013567 A MX 2020013567A MX 2020013567 A MX2020013567 A MX 2020013567A
Authority
MX
Mexico
Prior art keywords
film
diabetes
treatment
coated tablet
triazine derivative
Prior art date
Application number
MX2020013567A
Other languages
English (en)
Inventor
Sébastien Bolze
Maxime Laugier
Original Assignee
Poxel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Poxel filed Critical Poxel
Publication of MX2020013567A publication Critical patent/MX2020013567A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se refiere a una tableta recubierta con película que comprende un núcleo interno y un recubrimiento externo, en el que el núcleo interno comprende una alta proporción de un derivado de triazina específico, a saber, 2-amino-3,6-dihidro-4-di metilamino-6-metil-1,3,5-triazina y sus sales farmacéuticamente aceptables, y un aglutinante específico. También se dirige al uso de estas tabletas en el tratamiento de la diabetes y/o sus complicaciones. Esta invención se dirige además a un proceso específico para la fabricación de estas tabletas recubiertos con película, que implica una etapa de granulación en un mezclador de alto cizallamiento.
MX2020013567A 2018-06-14 2019-06-11 Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes. MX2020013567A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18305730 2018-06-14
PCT/EP2019/065158 WO2019238647A1 (en) 2018-06-14 2019-06-11 Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes

Publications (1)

Publication Number Publication Date
MX2020013567A true MX2020013567A (es) 2021-05-27

Family

ID=62778848

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013567A MX2020013567A (es) 2018-06-14 2019-06-11 Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes.

Country Status (13)

Country Link
US (1) US11813362B2 (es)
EP (1) EP3806828A1 (es)
JP (1) JP7266616B2 (es)
KR (1) KR20210003786A (es)
CN (1) CN112218623A (es)
AU (1) AU2019286326A1 (es)
BR (1) BR112020025112A2 (es)
CA (1) CA3103324A1 (es)
IL (1) IL279299A (es)
MX (1) MX2020013567A (es)
PH (1) PH12020551741A1 (es)
SG (1) SG11202010322XA (es)
WO (1) WO2019238647A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102879196B1 (ko) * 2019-09-27 2025-11-04 허큘레스 엘엘씨 이산화티타늄 비함유 백색 필름 코팅 조성물, 그를 제조하는 방법 및 그의 사용 방법
TW202135826A (zh) * 2019-12-13 2021-10-01 日商大日本住友製藥股份有限公司 製造性及溶出性優異之小型錠劑
KR20230091684A (ko) * 2021-12-16 2023-06-23 주식회사 종근당 다파글리플로진과 시타글립틴을 포함하며, 정제사이즈 축소를 통해 복용편의성이 향상된 약제학적 복합제제 및 이의 제조방법
CN116440075B (zh) * 2023-06-01 2025-05-06 苏州中化药品工业有限公司 一种干混悬剂及其制备方法
AU2024298701A1 (en) * 2023-07-27 2026-01-22 Bpsi Holdings Llc Film coating compositions with improved opacity and color uniformity and substrates coated therewith

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287366A (en) 1963-12-24 1966-11-22 American Cyanamid Co Novel 1, 2-dihydro-s-triazines
HUP0202076A3 (en) 1997-12-12 2003-12-29 Abbott Lab Triazine angiogenesis inhibitors
FR2804113B1 (fr) 2000-01-26 2004-06-18 Lipha Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
FR2853650B1 (fr) 2003-04-10 2006-07-07 Merck Sante Sas Procede de dedoublement d'amines utiles pour le traitement de desordres associes au syndrome d'insulino-resistance
US20070173434A1 (en) 2004-01-20 2007-07-26 Shi Guo Q Antidiabetic oxazolidinediones and thiazolidinediones
ATE470849T1 (de) 2005-08-11 2010-06-15 Sru Biosystems Inc Beugungsbasierter sensor, der markierungsfreie bindungserkennung und fluoreszenz-verstärkung kombiniert
FR2896161B1 (fr) 2006-01-13 2008-04-04 Merck Sante Soc Par Actions Si Utilisation de derives de triazines pour fabriquer un medicament ayant un effet cicatrisant ou angiogenique.
FR2896157B1 (fr) * 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline.
FR2896159B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline.
FR2896158B1 (fr) 2006-01-13 2008-09-12 Merck Sante Soc Par Actions Si Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase.
WO2008069222A1 (en) 2006-12-05 2008-06-12 Semiconductor Energy Laboratory Co., Ltd. Plasma display panel and field emission display
DE102007054416A1 (de) 2007-11-13 2009-05-14 Studiengesellschaft Kohle Mbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5- Triazin-Derivaten für die Behandlungen von Erkrankungen, die mit dem Insulinresistenz-Syndrom assoziiert sind
DE102008007314A1 (de) 2008-02-02 2009-08-06 Merck Patent Gmbh Verfahren zur Herstellung von 3,6-Dihydro-1,3,5-triazinderivaten
AU2009250149B2 (en) 2008-05-23 2013-05-23 Poxel Sas Process for the synthesis of 3,6-dihydro-1,3,5-triazine derivatives
WO2010012746A2 (en) 2008-07-29 2010-02-04 Poxel Process of isolating enantiomer components from enantiomer mixtures by particle-size-controlled crystallization
JP5667985B2 (ja) 2008-12-12 2015-02-12 ポクセル インスリンとトリアジンの組合せ及び糖尿病を治療するためのその使用
BRPI0922650A2 (pt) 2008-12-12 2017-07-11 Poxel Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina
DK2395968T3 (da) 2009-02-13 2024-03-04 Boehringer Ingelheim Int Farmaceutisk sammensætning omfattende glucopyranosyldiphenylmethanderivater, farmaceutisk doseringsform deraf, fremgangsmåde til deres forberedelse og anvendelser deraf til forbedret glykæmisk kontrol hos en patient
US8742102B2 (en) 2009-03-26 2014-06-03 Poxel Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
FR2948027A1 (fr) 2009-07-17 2011-01-21 Merck Sante Sas Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion
JP5707489B2 (ja) 2010-06-09 2015-04-30 ポクセル・エスアーエスＰｏｘｅｌｓａｓ １型糖尿病の処置
TWI436768B (zh) 2010-06-09 2014-05-11 Poxel 第２型糖尿病之治療
HUE026090T2 (en) 2010-12-01 2016-05-30 Poxel Separation of enantiomeric triazine derivatives using tartaric acid
EP2468261A1 (en) * 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
US9211263B2 (en) 2012-01-06 2015-12-15 Elcelyx Therapeutics, Inc. Compositions and methods of treating metabolic disorders
US20160151461A1 (en) 2013-03-14 2016-06-02 The Trustees Of The University Of Pennsylvania Cardio-Metabolic and Vascular Effects of GLP-1 Metabolites
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ITMI20130874A1 (it) * 2013-05-29 2014-11-30 Zambon Spa Compresse deglutibili di n-acetilcisteina
JP6615109B2 (ja) 2014-02-28 2019-12-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｄｐｐ−４阻害薬の医学的使用
US10285973B2 (en) 2014-11-10 2019-05-14 Merck Sharp & Dohme Corp. SGLT-2 inhibitors for treating metabolic disorders in patients with renal impairment or chronic kidney disease
CN105990398B (zh) 2015-02-16 2019-01-11 上海和辉光电有限公司 有机发光二极管显示器及其制造方法
CN118286237A (zh) 2016-03-16 2024-07-05 勃林格殷格翰国际有限公司 包含恩格列净的药物组合物及其用途
CN111163782A (zh) 2017-10-02 2020-05-15 普克塞尔公司 治疗射血分数保留型心力衰竭的方法
JP7635474B2 (ja) 2018-06-06 2025-02-26 プリスティーヌ・エスアーエス 慢性腎疾患を持つ糖尿病対象を治療する方法

Also Published As

Publication number Publication date
CN112218623A (zh) 2021-01-12
SG11202010322XA (en) 2020-11-27
JP2021526506A (ja) 2021-10-07
EP3806828A1 (en) 2021-04-21
PH12020551741A1 (en) 2021-06-07
US20210212951A1 (en) 2021-07-15
AU2019286326A1 (en) 2020-12-10
US11813362B2 (en) 2023-11-14
WO2019238647A1 (en) 2019-12-19
CA3103324A1 (en) 2019-12-19
BR112020025112A2 (pt) 2021-03-23
KR20210003786A (ko) 2021-01-12
IL279299A (en) 2021-01-31
JP7266616B2 (ja) 2023-04-28

Similar Documents

Publication Publication Date Title
PH12020551741A1 (en) Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes
ZA202403426B (en) Substituted 6-azabenzimidazole compounds as hpk1 inhibitors
JOP20190186A1 (ar) مركب كينازولين
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
MY196243A (en) Dihydropyrimidine Compounds and Their Application In Pharmaceuticals
SA519401336B1 (ar) تركيبة صيدلية
MY194405A (en) Dihydropyrimidine compounds and uses thereof in medicine
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
SA520411524B1 (ar) مركبات تنشيط القسيم العضلي ثنائي الأميد واستخداماتها
GEAP201914678A (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
PH12019501955A1 (en) Tri-cycle compound and applications thereof
EP4454712A3 (en) Use of sepiapterin and metabolites thereof to treat radiation exposure
PH12016500120A1 (en) Anti-tuberculosis stable pharmaceutical composition in a form of a coated tablet comprising granules of isoniazid and granules of rifapentine and its process of preparation
MY185942A (en) Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse
JOP20200090A1 (ar) عملية لتحضير بنزوثيوفين-2 يل بورونات
PH12020500436A1 (en) Aromatic derivative, preparation method for same, and medical applications thereof
PH12021550572A1 (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
MX2021005936A (es) Metodos farmaceuticos.
SA516370446B1 (ar) تركيبة صيدلانية مستقرة مضادة للدرن في صورة قرص قابل للتشتت يحتوي على حبيبات إيزونيازيد وحبيبات ريفابنتين، وعملية لتحضيرها
MX2019005005A (es) Tableta de liberacion extendida que comprende un farmaco de perdida de peso.
HK1254389A1 (zh) 含有药物的立即释放片剂和用於形成片剂的方法
NZ723518A (en) Salts and solid form of a btk inhibitor